Showing 1–12 of 22 resultsSorted by latest
Medical Devices & Equipments
BD has announced that it will combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust structure, with a total value of $17.5bn.
Stryker’s operational excellence remains a cornerstone strength, evidenced by
consistent margin expansion and disciplined capital allocation.
Merck & Co which is known as Keytruda dependent entity is now a diversified pharmaceutical powerhouse.
The Transcatheter Aortic Valve Replacement (TAVR) business remains Edwards’ primary revenue engine, contributing $1.13 billion in Q2, or roughly three fourths of total sales, with 8.9% year-over-year growth.
The broad U.S. launch of Da Vinci 5 is not a simple product refresh, but the start of a multi-year “super-cycle” that will drive upgrades across the entire installed base.
Medtronic has effectively completed its multi-year transformation and has now begun a period of steady and reliable performance.
Boston Scientific (BSX) is focused on expanding its global manufacturing footprint, with notable investments in the U.S., including a new site in Georgia and increased capacity in Minnesota to support long-term growth.
Stryker reported strong organic sales growth of 10.1% in Q1 2025, led by double-digit growth in MedSurg and neurotechnology, and high single-digit growth in ortho paedics, despite one fewer selling day and a tough 10% year-over-year comparison.
ABT acknowledges that the evolving global economic environment, influenced by new tariff policies, presents a challenge.
Medtronic (MDT) reported its ninth straight quarter of mid-single-digit revenue growth, with strong results across several key areas. Cardiac Ablation Solutions grew 22%, driven by strong demand for its Pulse Field
Ablation (PFA) products.
BSX reported 31% operational growth in the U.S. for Q4 2024 and 21% for the full year, with double-digit growth in six of eight business units.
Stryker (SYK) has announced the sale of its Spinal Implants business, which did not meet performance expectations